BiotechTube

fibrinolytic therapy or combination reduced fibrinolytic therapy

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction

Trial Timeline

Jun 1, 2001 → Oct 1, 2007

NCT ID
NCT00245648

About fibrinolytic therapy or combination reduced fibrinolytic therapy

fibrinolytic therapy or combination reduced fibrinolytic therapy is a phase 3 stage product being developed by Eli Lilly for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT00245648. Target conditions include Myocardial Infarction.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00245648Phase 3Completed

Competing Products

20 competing products in Myocardial Infarction

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
76
AbciximabEli LillyApproved
85
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
77
Regadenoson + gadofoveset trisodiumAstellas PharmaPhase 2
52
Half-dose of the Tc99-m sestamibi (Cardiolite)Astellas PharmaPre-clinical
23
No interventionAstellas PharmaPre-clinical
23
Empagliflozin + PlaceboEli LillyPhase 3
77
Abciximab + Abciximab placeboEli LillyPhase 3
77
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
77
AbciximabEli LillyApproved
85
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximabEli LillyPhase 3
77
abciximabEli LillyApproved
85
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
65
Thrombolytic therapyEli LillyPre-clinical
23
TicagrelorAstraZenecaPre-clinical
23
TicagrelorAstraZenecaPhase 2
52
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
23
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
33
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
77
RosuvastatinAstraZenecaPhase 3
77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85